Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951065 | 0.91 | TBXA2R (0.43) | TBXA2RTBXAS1HDAC3HDAC1HDAC2 | |
| SCHEMBL2810391 | 0.81 | TBXA2R (0.55) | TBXA2RAKR1B1HDAC3HDAC1HDAC2 | |
| SCHEMBL2816820 | 0.80 | TBXA2R (0.47) | TBXA2RAKR1B1HDAC3HDAC1HDAC2 | |
| SCHEMBL2815715 | 0.78 | MCHR1 (0.49) | TBXA2RPTGDR2HDAC3HDAC1HDAC2 | |
| SCHEMBL2814157 | 0.78 | HTR6 (0.40) | TBXA2RPTGDR2HRH1HTR6 | |
| SCHEMBL2809345 | 0.78 | TBXA2R (0.41) | TBXA2RTBXAS1HRH1HTR6 | |
| SCHEMBL2814074 | 0.77 | TBXA2R (0.40) | TBXA2RTBXAS1HRH1HTR6 | |
| SCHEMBL2813886 | 0.77 | TBXA2R (0.41) | TBXA2RPTGDR2TBXAS1HRH1HTR6 | |
| SCHEMBL2812789 | 0.77 | HRH1 (0.48) | TBXA2RTBXAS1HDAC3HDAC1HDAC2 | |
| SCHEMBL2812940 | 0.77 | TBXA2R (0.45) | TBXA2RAKR1B1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2344505-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011008312-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010036998-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885TBXA2R 419/4885AKR1B1 460/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885TBXA2R 419/4885AKR1B1 460/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885TBXA2R 419/4885AKR1B1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.